The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer
Menée entre 2017 et 2019 sur 126 patients atteints d'un adénocarcinome canalaire du pancréas à la limite de la résécabilité, cet essai multicentrique randomisé de phase II évalue l'intérêt, du point de vue du taux de survie globale à 18 mois, de l'ajout d'une radiothérapie hypofractionnée à une chimiothérapie de type FOLFIRINOX modifié
Pancreatic ductal adenocarcinoma (PDAC) remains the third leading cause of cancer-associated deaths in the US and is on pace to become the second leading cause of cancer-related mortality. Improvements in outcomes for those affected by pancreas cancer are primarily because of more effective systemic therapies. This includes the approval of olaparib maintenance therapy for patients with germline BRCA-variated metastatic pancreatic cancer and FOLFIRINOX or gemcitabine/capecitabine adjuvant chemotherapy regimens based off the PRODIGE24-ACCORD and ESPAC-4 trials, which demonstrated an improvement in overall survival.
JAMA Oncology , éditorial, 2021